Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

This study is testing whether a PARP inhibitor drug called fluzoparib (a type of targeted oral therapy) given before surgery can help shrink tumors in women with early to locally advanced triple-negative breast cancer who carry a BRCA1 or BRCA2 gene mutation. BRCA mutations make cancer cells more sensitive to this type of drug. **You may be eligible if...** - You are a woman between 18 and 70 years old with newly diagnosed triple-negative breast cancer (hormone receptor-negative, HER2-negative) - Your tumor is at least 2 cm and at stage II or III - You carry a confirmed BRCA1 or BRCA2 gene mutation - You have not yet received any cancer treatment - Your overall health and organ function meet required levels **You may NOT be eligible if...** - Your cancer has spread to other parts of the body (metastatic) - You have bilateral or inflammatory breast cancer - You have previously received a PARP inhibitor drug - You have a history of heart failure or severe irregular heartbeat - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.